Cystic Echinococcus Clinical Trial
Official title:
Periprosthetic Pathologic Fracture Following Tibial Echinococcosis: A Case Report
Verified date | August 2018 |
Source | Centro Hospitalar do Medio Tejo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cystic Echinococcus in the bone is rare, comprising 0.5% to 2.5% of all human hydatidosis Association of Hydatid disease to pathologic fractures involving knee prosthesis have not yet been described A combined surgical and medical approach is of paramount importance to avoid recurrence Resulting osseus defects is challenging and require specific prosthesis when treating this entity.
Status | Completed |
Enrollment | 1 |
Est. completion date | July 1, 2017 |
Est. primary completion date | July 1, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion criteria - Patients with echinococcus infection - Patients which this infection compromises knee stability. Exclusion criteria - bacterial infection - immunocompromised patients |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centro Hospitalar do Medio Tejo |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain assessed by numerical rating scale (NRS) | measured with numerical rating scale (NRS), ranging from 0 to 10 (minimum to maximum pain) | 6 years |